Improving Lutetium Therapy for Advanced Prostate Cancer
MELT: Modulation of PSMA Expression for Lutetium Therapy
This project aims to make a special radiation treatment for advanced prostate cancer more effective by helping cancer cells better absorb the treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11128647 on NIH RePORTER |
What this research studies
Advanced prostate cancer that has become resistant to standard treatments is a very serious condition, and we are always looking for better ways to help patients. This project focuses on a promising radiation treatment called Lutetium therapy, which targets a specific marker called PSMA found on most prostate cancer cells. We want to learn how to make cancer cells show more PSMA, so the treatment can find and attack them more effectively. We also aim to understand why some tumors respond better to this radiation than others. Our goal is to find new ways to boost the treatment's power, either by increasing PSMA on cancer cells or by making the cells more sensitive to the radiation, which could lead to more successful clinical trials.
Who could benefit from this research
Good fit: Patients with castrate-resistant prostate cancer who might be candidates for PSMA-targeted therapies could potentially benefit from future clinical trials informed by this research.
Not a fit: Patients whose prostate cancer does not express PSMA or who have early-stage prostate cancer may not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this work could lead to new combination therapies that significantly improve the effectiveness of Lutetium therapy for patients with advanced prostate cancer.
How similar studies have performed: Small studies have already shown remarkable efficacy of PSMA radioligand therapy in heavily pretreated patients, indicating a strong foundation for this research.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Hope, Thomas a. — University of California, San Francisco
- Study coordinator: Hope, Thomas a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.